Abstract 15P
Background
PD-1/PD-L1 blockade combined with chemoradiotherapy putatively benefited patients with dMMR/MSI-H colorectal cancer. However, the effect of PD-L1 blockade plus chemoradiotherapy for pMMR/MSS rectal cancer remains unclear, and the mechanisms influencing therapeutic response need further exploration.
Methods
A phase II, open-labeled, study was conducted to evaluate the efficacy and safety of adding Atezolizumab (PD-L1 blockade) to neoadjuvant chemoradiotherapy in MSS locally advanced rectal cancer (LARC). All patients received long-course radiotherapy plus capecitabine followed by three 21-day cycles Atezolizumab and TME surgery. Single cell RNA sequencing was performed on surgical resection samples.
Results
Twelve patients were recruited with 100% R0 resection. 50% (n=6) of MPR rate was observed, 3 of these patients achieved pCR. Interestingly, the proportion of T cells in the non-MPR group was significantly higher than in the MPR group, particularly TIGIT+ CD8+ T cells. However, further analysis indicated that the T cells in the non-MPR group were functionally exhausted. Compared to the MPR group, the interaction between NECTIN2+ cancer-associated fibroblasts and TIGIT+ CD8+ T cells was significantly enhanced in the non-MPR group. Mechanistically, the NECTIN2-TIGIT interaction limit the cytotoxic response by CD8+ T cells through inhibition of cyclic GMP-AMP synthase (cGAS)-STING pathway. Moreover, addition of TIGIT blockade to PD-L1 blockade plus chemoradiotherapy significantly enhances the therapeutic efficacy in MSS rectal cancer in vitro and in vivo.
Conclusions
NECTIN2-TIGIT serves as a crucial immune checkpoint for the efficacy of PD-L1 blockade plus chemoradiotherapy in MSS locally advanced rectal cancer, and the supplementary application of TIGIT blockade presents a rational approach for an immunotherapeutic combination strategy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
J. Xu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1781P - Multi-omics of soft tissue sarcomas with complex karyotypes: Investigating genomic and transcriptomic differences between cell lines of the same subtype
Presenter: Miriam Arrulo
Session: Poster session 07
1782P - Assessing the role of denosumab in managing aneurysmal bone cysts: A scoping review
Presenter: Vinesh Sandhu
Session: Poster session 07
1783P - Genetic predisposition in adult sarcoma patients: Beyond TP53
Presenter: Olivia Rohr
Session: Poster session 07
1784TiP - Pasireotide as maintenance treatment in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor: The PAMSARC study
Presenter: Richard Schlenk
Session: Poster session 07
1785TiP - PERELI, a phase II, open label, multicenter study of pemigatinib and retifanlimab in advanced dedifferentiated liposarcoma
Presenter: Helena Nyström
Session: Poster session 07
1787P - Intracranial response in patients (pts) with baseline (BL) brain metastases (BM) and extensive-stage (ES) small cell lung cancer (SCLC) treated with ifinatamab deruxtecan (I-DXd) in the IDeate-Lung01 study
Presenter: Melissa Johnson
Session: Poster session 07
1790P - Phase II data of lurbinectedin (LUR) and irinotecan (IRI) in relapsed small cell lung cancer (SCLC) patients (pts) with chemotherapy-free interval (CTFI)>30 days (d)
Presenter: Jon Zugazagoitia
Session: Poster session 07